Search clinical trials for: Y-90 resin microspheres

Total 452926 results

GrandPharma (China) Co., Ltd.

Not yet recruiting

Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer

Colorectal Neoplasms

China
Methodist Health System

Recruiting

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

Hepatocellular Carcinoma

United States
Massachusetts General Hospital
National Institutes of Health (NIH); Implant Sciences

Terminated

Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators

Spinal Neoplasms

United States
M.D. Anderson Cancer Center
Sirtex Medical

Recruiting

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Metastases

United States
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Boston Scientific Corporation

Completed

Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option (Y-90HDE)

Liver Cancer | Hepatoma
Spectrum Pharmaceuticals, Inc
Bayer

Completed

Zevalin Post-marketing Surveillance in Japan (ZEVALIN-DUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
Bayer

Completed

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Lymphoma, Follicular | Non-Hodgkin Lymphoma

Belgium
Emory University
National Cancer Institute (NCI); Sirtex Medical

Withdrawn

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Metastatic Carcinoma in the Liver

United States
Boston Scientific Corporation

Recruiting

A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (FRONTIER)

Glioblastoma Multiforme | Recurrent Glioblastoma

United States
University of Florida
Novatek

Not yet recruiting

Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment

Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
BTG International Inc.

Completed

Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma

Cholangiocarcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Allan Tsung

Withdrawn

Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
Southwestern Regional Medical Center

Completed

Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors

Carcinoma, Hepatocellular | Liver Neoplasms

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery

Metastatic Cancer | Liver Cancer

United States
Leo W. Jenkins Cancer Center

No longer available

Therasphere® for Treatment of Unresectable Primary Liver Cancer and Metastatic Liver Cancer

Neoplasm Metastasis | Carcinoma, Hepatocellular

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma...

United States
University of Michigan Rogel Cancer Center
Department of Health and Human Services; National Institute for Biomedical...

Recruiting

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Liver Malignancy

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaborators

Withdrawn

Y-90 Versus SBRT for Inoperable HCC

Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditions

United States
European Institute of Oncology
Agenzia Italiana del Farmaco

Recruiting

Neoadjuvant PRRT With Y-90-DOTATOC in pNET (NeoNet)

Pancreatic Neuroendocrine Tumor

Italy
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Internal Radiation Therapy in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
City of Hope Medical Center

No longer available

Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

Stage IV Liver Cancer | Stage IVA Liver Cancer | Stage IVB Liver Cancer | Metastatic Liver Carcinoma

United States
Eastern Hepatobiliary Surgery Hospital

Completed

Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma | Radioembolization

China
Thomas Jefferson University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

Hepatocellular Carcinoma

United States
Bayer

Completed

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Italy, Canada, Switzerland, Netherlands, United Kingdom, Portugal, Germany, Sweden, Denmark, Norway
Chandrikha Chandrasekharan
AstraZeneca; Biocompatibles UK Ltd

Suspended

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C)

Metastatic Colorectal Cancer | Colorectal Neoplasms | Rectal Cancer | Colon Cancer | Colorectal Cancer Metastatic | Liver Metastases | Colo-rectal Cancer | Colorectal Carcinoma | Colorectal Adenocarcinoma | Liver Metastasis Colon Cancer

United States
University of Miami

Completed

Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors

Liver Cancer | Hepatic Tumors

United States
Goshen Health System

Unknown

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

Pancreatic Cancer | Metastatic Cancer

United States
Ondokuz Mayıs University

Not yet recruiting

The Effect of Hope Placement Program on Dıagnosed Wıth MS

Multiple Sclerosis

Turkey
University Hospital Southampton NHS Foundation...
Royal Free and University College Medical School

Completed

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

Lymphoma | Myeloma | Acute Leukaemia | Chronic Leukaemia

United Kingdom
Alnylam Pharmaceuticals

Approved for marketing

Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1

Primary Hyperoxaluria

Belgium
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; AstraZeneca; Sirtex Medical

Recruiting

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Cholangiocarcinoma | Bile Duct Cancer | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic | Metastatic Intrahepatic Cholangiocarcinoma

United States
Alnylam Pharmaceuticals

Active, not recruiting

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 (ILLUMINATE-B)

Primary Hyperoxaluria Type 1 (PH1) | Primary Hyperoxaluria

United States, France, United Kingdom, Israel, Germany
North Dakota State University
National Institutes of Health (NIH)

Completed

Pharmacokinetic Properties of Sertraline Before and After Gastric Bypass Surgery

Roux en Y Gastric Bypass Surgery

United States
Yale University

Completed

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Liver Neoplasms

United States
The University of Texas Health Science Center,...

Terminated

Prospective Tumor Response Evaluation (Liver)

Hepatocellular Cancer | Metastatic Liver Cancer

United States
Sirtex Medical

Completed

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (SIRFLOX)

Colorectal Cancer | Liver Metastases | Colorectal Carcinoma

United States, Israel, Australia, Belgium, New Zealand, Spain, Germany, Switzerland, Italy, France, Poland
Alnylam Pharmaceuticals

Active, not recruiting

A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (ILLUMINATE-C)

Primary Hyperoxaluria Type 1 | Primary Hyperoxaluria

United States, Italy, France, Lebanon, Belgium, Netherlands, Israel, United Arab Emirates, Australia, Jordan, Turkey
M.D. Anderson Cancer Center
Novartis Pharmaceuticals; BTG International Inc.

Withdrawn

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Liver Cancer
CABYC
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Completed

Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) (LCM-04-02)

Mantle Cell Lymphoma

Spain
Akdeniz University

Completed

The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients

Cervix Cancer | Cancer of Ovary | Endometrium Cancer

Turkey
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditions

United States
Ankara Diskapi Training and Research Hospital

Completed

The Comparison of the Methods Applied in Bariatric Surgery in Terms of Preoxygenation Time

Time to Reach 90% Endtidal Oxygen During Preoxygenation

Turkey
Temple University

Completed

Influence of Supportive Sandals on Y-Balance Performance on Healthy Young Individuals

Y-balance Performance

United States
University of Pittsburgh
National Cancer Institute (NCI)

Completed

Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery

Liver Cancer

United States
University of Colorado, Denver
AstraZeneca

Withdrawn

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Colorectal Cancer
Northwestern University
National Cancer Institute (NCI)

Completed

Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States

Search clinical trials for: Y-90 resin microspheres

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations